AI steps in to validate promising leukemia treatment without a traditional trial

This study uses artificial intelligence and real-world patient data to compare a new drug combination (venetoclax plus decitabine) against standard chemotherapy for elderly patients (ages 60-75) with acute myeloid leukemia (AML). Researchers will analyze records from nearly 2,000 patients to see if the newer treatment leads to better outcomes and higher chances of a bone marrow transplant. No new treatments are given; the goal is to gather knowledge and validate the effectiveness of this approach.